FORM 4

UNITED

Washington, D.C. 20549

| STATES | SECURITIES | AND EXCH | IANGE C | OMMISSION |
|---------------|-------------------|----------|---------|-----------|
| | | | | |

| OMB APPROVAL | | | | | | | | |
|-------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average burde | n | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* <u>Kaye Edward M. MD</u> | | | | 2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK] | | | | | | | (Che | | ble) | 1 | 0% Ow | ner | | |
|--|--|------------|-------------|---|---|---|--|-----------------------|---|---|--|--|---|--|------------|-------|---------|--|
| (Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. | | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/03/2024 | | | | | | | | Officer (give title below) CEO Other (specify below) | | | | беспу | | |
| 45 WIGGINS AVENUE | | | | | If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Inc | 6. Individual or Joint/Group Filing (Check Applicable | | | | | |
| (Street) BEDFORI | D MA | Α (| 01730 | | | T. II AMONUMON, Date of Original Fried (worth/Day/Teal) | | | | | | Line) | | | | | | |
| (City) | (Sta | ate) (| Zip) | | | Person | | | | | | | | | | | | |
| | | Tal | ole I - Non | -Deriv | ative | Se | curitie | s Acqı | uired, | Disp | osed of, | or Bene | ficially | Owned | | | | |
| 1. Title of Security (Instr. 3) 2. Trans Date (Month/I | | | | action 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) (Disposed Of (D) (Instr. 3, 4) | | (A) or 3, 4 and 5) | 5. Amount Securities Beneficial Owned Fo Reported | ly (I | i. Ownersh form: Dire D) or Indir I) (Instr. 4) | ct II ect B | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | | |
| | | | | | | | | Code | v | Amount | (A) or (D) | Price | Transactio | | | (| 1150.4) | |
| Common Stock 12/03 | | | | 3/2024 | 024 M 26,500 A \$0 | | 75,0 | 75,091 | | | | | | | | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | rive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any | | | ransaction Derivative ode (Instr. Securities | | ve es d (A) or ed of | 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4) | | es g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficially Owned Following Reported Transaction | Owi For Dire or li (l) (l | Ownership Form: Direct (D) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| | | | | C | ode V | v | (A) | (D) | Date Exercis | sable | Expiration Date | Title | Amount or Number of Shares | | (Instr. 4) | (5) | | |
| Performance Stock Units | (1) | 12/03/2024 | | Α | \ (2) | | 53,000 | | (3) |) | 12/03/2025 | Common Stock | 53,000 | \$0 | 53,000 | | D | |
| Performance | (1) | 12/03/2024 | | | М | | | 26 500 | (3) |) | 12/03/2025 | Common | 26 500 | \$0 | 26 500 | | D | |

Explanation of Responses:

- 1. Each performance stock unit represents a right to receive one share of the Issuer's common stock.
- 2. This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.
- 3. Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

/s/ Jonathan Allan, Attorney-in-12/05/2024 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.